Skip to main content
Top
Published in: European Journal of Epidemiology 10/2011

01-10-2011

Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening

Authors: Ben Schöttker, Elke Raum, Dietrich Rothenbacher, Heiko Müller, Hermann Brenner

Published in: European Journal of Epidemiology | Issue 10/2011

Login to get access

Abstract

The aim of this analysis is to compare screening strategies with haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) or combined measures in the identification of individuals at high risk for diabetes. Applying American Diabetes Association thresholds for FPG and HbA1c screening, 6,803 subjects free of diabetes were classified as non-diabetic, pre-diabetic and possibly diabetic by FPG (<100, 100–125 and >125 mg/dl) and HbA1c (<5.7, 5.7–6.4 and >6.4%). Hazard ratios, sensitivity and specificity were estimated for individuals with pre-diabetes with respect to incident diabetes in the following 5 years. Areas under the receiver operating characteristic curves (AUC) were estimated for levels of FPG ≤ 125 mg/dl and HbA1c ≤ 6.4% in diabetes prediction. Although FPG and HbA1c screenings poorly agreed in classifying individuals as pre-diabetic, hazard ratios [95% confidence interval] for incident diabetes were similarly increased in univariate models in the two pre-diabetic groups: FPG 100–125 mg/dl, 4.72 [3.69; 6.05]; HbA1c 5.7–6.4%, 3.97 [3.05; 5.23]. HbA1c and FPG had comparable AUCs (FPG, 0.732; HbA1c, 0.725) and consequently similar 5-year sensitivities and specificities for their pre-diabetes definitions (when the lower cut-off for HbA1c-defined pre-diabetes was increased to a level between 5.8 and 5.9%). Combining HbA1c and FPG increased the AUC to 0.778, and a further increase to 0.817 was seen with additional inclusion of conventional risk factors. FPG and HbA1c have comparable (yet insufficient) abilities in identifying individuals at high risk for diabetes. Effectiveness of a diabetes screening program could be improved by a risk score including FPG and HbA1c.
Appendix
Available only for authorised users
Literature
1.
go back to reference Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11(17):iii–xi, 1. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11(17):iii–xi, 1.
2.
go back to reference American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(1):S11–61. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(1):S11–61.
3.
go back to reference Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of HbA1c screening criterion on the diagnosis of pre-diabetes among US adults. Diabetes Care. 2010;33:2190–95; published online ahead of print, doi:10.2337/dc10-0752. Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of HbA1c screening criterion on the diagnosis of pre-diabetes among US adults. Diabetes Care. 2010;33:2190–95; published online ahead of print, doi:10.​2337/​dc10-0752.
4.
go back to reference American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care. 2007;30(9):2399–400. American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care. 2007;30(9):2399–400.
5.
go back to reference American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(1):S11–61. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(1):S11–61.
6.
go back to reference Gambino R. Glucose: a simple molecule that is not simple to quantify. Clin Chem. 2007;53(12):2040–1.PubMedCrossRef Gambino R. Glucose: a simple molecule that is not simple to quantify. Clin Chem. 2007;53(12):2040–1.PubMedCrossRef
7.
go back to reference Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281(13):1203–10.PubMedCrossRef Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281(13):1203–10.PubMedCrossRef
8.
go back to reference Lauritzen T, Sandbaek A, Skriver K, Borch-Johnson K. HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark. Diabetologia. 2011 Feb; published online ahead of print doi:10.1007/s00125-011-2077-9. Lauritzen T, Sandbaek A, Skriver K, Borch-Johnson K. HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark. Diabetologia. 2011 Feb; published online ahead of print doi:10.​1007/​s00125-011-2077-9.
9.
go back to reference Raum E, Lietzau S, Stegmaier C, Brenner H, Rothenbacher D. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany. Pharmacoepidemiol Drug Saf. 2008;17(5):485–94.PubMedCrossRef Raum E, Lietzau S, Stegmaier C, Brenner H, Rothenbacher D. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany. Pharmacoepidemiol Drug Saf. 2008;17(5):485–94.PubMedCrossRef
10.
go back to reference Gao L, Weck MN, Stegmaier C, Rothenbacher D, Brenner H. Alcohol consumption, serum gamma-glutamyltransferase, and helicobacter pylori infection in a population-based study among 9733 older adults. Ann Epidemiol. 2010;20(2):122–8.PubMedCrossRef Gao L, Weck MN, Stegmaier C, Rothenbacher D, Brenner H. Alcohol consumption, serum gamma-glutamyltransferase, and helicobacter pylori infection in a population-based study among 9733 older adults. Ann Epidemiol. 2010;20(2):122–8.PubMedCrossRef
11.
go back to reference Richter M, Brand H, Rossler G. [Socio-economic differences in the utilisation of screening programmes and health promotion measures in North Rhine-Westphalia, Germany]. Gesundheitswesen. 2002;64(7):417–23.PubMedCrossRef Richter M, Brand H, Rossler G. [Socio-economic differences in the utilisation of screening programmes and health promotion measures in North Rhine-Westphalia, Germany]. Gesundheitswesen. 2002;64(7):417–23.PubMedCrossRef
12.
go back to reference John WG, Mosca A, Weykamp C, Goodall I. HbA(1c) standardisation: history, science and politics. Clin Biochem Rev. 2007;28(4):163–8.PubMed John WG, Mosca A, Weykamp C, Goodall I. HbA(1c) standardisation: history, science and politics. Clin Biochem Rev. 2007;28(4):163–8.PubMed
13.
go back to reference Olafsdottir E, Aspelund T, Sigurdsson G, Thorsson B, Benediktsson R, Harris TB, et al. Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in a population-based study of older persons: from the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik). Eur J Epidemiol. 2009;24(6):307–14.PubMedCrossRef Olafsdottir E, Aspelund T, Sigurdsson G, Thorsson B, Benediktsson R, Harris TB, et al. Unfavourable risk factors for type 2 diabetes mellitus are already apparent more than a decade before onset in a population-based study of older persons: from the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik). Eur J Epidemiol. 2009;24(6):307–14.PubMedCrossRef
14.
go back to reference Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167(10):1068–74.PubMedCrossRef Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167(10):1068–74.PubMedCrossRef
15.
go back to reference Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33:613–9.CrossRef Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33:613–9.CrossRef
17.
go back to reference Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and prediabetes with proposed A1c-based diagnostic criteria. Diabetes Care. 2010;33(10):2184–9 published online ahead of print. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and prediabetes with proposed A1c-based diagnostic criteria. Diabetes Care. 2010;33(10):2184–9 published online ahead of print.
18.
go back to reference Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010;33(9):2104–9.PubMedCrossRef Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010;33(9):2104–9.PubMedCrossRef
19.
go back to reference Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G, et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care. 2009;32(4):644–6.PubMedCrossRef Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G, et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care. 2009;32(4):644–6.PubMedCrossRef
20.
go back to reference Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the Atherosclerosis Risk In Communities study. Diabetes. 2010;59(8):2020–6.PubMedCrossRef Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the Atherosclerosis Risk In Communities study. Diabetes. 2010;59(8):2020–6.PubMedCrossRef
21.
go back to reference Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275–8.PubMedCrossRef Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275–8.PubMedCrossRef
22.
go back to reference Voulgari C, Tentolouris N. Accuracy and precision of glucose monitoring are relevant to treatment decision-making and clinical outcome in hospitalized patients with diabetes. Diabetes Technol Ther. 2011;13(7):723–30.PubMedCrossRef Voulgari C, Tentolouris N. Accuracy and precision of glucose monitoring are relevant to treatment decision-making and clinical outcome in hospitalized patients with diabetes. Diabetes Technol Ther. 2011;13(7):723–30.PubMedCrossRef
23.
go back to reference Goodall I, Colman PG, Schneider HG, McLean M, Barker G. Desirable performance standards for HbA(1c) analysis - precision, accuracy and standardisation: consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clin Chem Lab Med. 2007;45(8):1083–97.PubMedCrossRef Goodall I, Colman PG, Schneider HG, McLean M, Barker G. Desirable performance standards for HbA(1c) analysis - precision, accuracy and standardisation: consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clin Chem Lab Med. 2007;45(8):1083–97.PubMedCrossRef
24.
go back to reference Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011;3(1):67–73.PubMedCrossRef Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011;3(1):67–73.PubMedCrossRef
25.
go back to reference Thomas MC, Tsalamandris C, MacIsaac RJ, Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis. 2006;48(4):537–45.PubMedCrossRef Thomas MC, Tsalamandris C, MacIsaac RJ, Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis. 2006;48(4):537–45.PubMedCrossRef
26.
go back to reference Nathan DM. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327–34.CrossRef Nathan DM. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327–34.CrossRef
27.
go back to reference Soranzo N, Senna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic Loci influence hemoglobin A1c levels via Glycemic and Nonglycemic pathways. Diabetes. 2010;59:3229–39.PubMedCrossRef Soranzo N, Senna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at 10 genomic Loci influence hemoglobin A1c levels via Glycemic and Nonglycemic pathways. Diabetes. 2010;59:3229–39.PubMedCrossRef
28.
go back to reference Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ). 2005;128:1–11. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ). 2005;128:1–11.
29.
go back to reference Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2006;29(7):1619–25.PubMedCrossRef Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2006;29(7):1619–25.PubMedCrossRef
30.
go back to reference Nakagami T, Tajima N, Oizumi T, Karasawa S, Wada K, Kameda W, et al. Hemoglobin A1c in predicting progression to diabetes. Diabetes Res Clin Pract. 2010;87(1):126–31.PubMedCrossRef Nakagami T, Tajima N, Oizumi T, Karasawa S, Wada K, Kameda W, et al. Hemoglobin A1c in predicting progression to diabetes. Diabetes Res Clin Pract. 2010;87(1):126–31.PubMedCrossRef
31.
go back to reference Wannamethee SG, Papacosta O, Whincup PH, Thomas MC, Carson C, Lawlor DA, et al. The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in older men and women. Diabet Med. 2011;28(1):23–30.PubMedCrossRef Wannamethee SG, Papacosta O, Whincup PH, Thomas MC, Carson C, Lawlor DA, et al. The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in older men and women. Diabet Med. 2011;28(1):23–30.PubMedCrossRef
33.
go back to reference Glumer C, Borch-Johnsen K, Colagiuri S. Can a screening programme for diabetes be applied to another population? Diabet Med. 2005;22(9):1234–8.PubMedCrossRef Glumer C, Borch-Johnsen K, Colagiuri S. Can a screening programme for diabetes be applied to another population? Diabet Med. 2005;22(9):1234–8.PubMedCrossRef
34.
go back to reference Raum E, Rothenbacher D, Low M, Stegmaier C, Ziegler H, Brenner H. Changes of cardiovascular risk factors and their implications in subsequent birth cohorts of older adults in Germany: a life course approach. Eur J Cardiovasc Prev Rehabil. 2007;14(6):809–14.PubMedCrossRef Raum E, Rothenbacher D, Low M, Stegmaier C, Ziegler H, Brenner H. Changes of cardiovascular risk factors and their implications in subsequent birth cohorts of older adults in Germany: a life course approach. Eur J Cardiovasc Prev Rehabil. 2007;14(6):809–14.PubMedCrossRef
35.
go back to reference Löw M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H. [Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study)]. Dtsch Med Wochenschr. 2004;129(49):2643–7.PubMedCrossRef Löw M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H. [Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study)]. Dtsch Med Wochenschr. 2004;129(49):2643–7.PubMedCrossRef
36.
go back to reference Manley SE, Sikaris KA, Lu ZX, Nightingale PG, Stratton IM, Round RA, et al. Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabet Med. 2009;26(2):115–21.PubMedCrossRef Manley SE, Sikaris KA, Lu ZX, Nightingale PG, Stratton IM, Round RA, et al. Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabet Med. 2009;26(2):115–21.PubMedCrossRef
Metadata
Title
Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening
Authors
Ben Schöttker
Elke Raum
Dietrich Rothenbacher
Heiko Müller
Hermann Brenner
Publication date
01-10-2011
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 10/2011
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-011-9619-9

Other articles of this Issue 10/2011

European Journal of Epidemiology 10/2011 Go to the issue